Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Lipum and the Scientific Advisory Board meet for the annual workshop

News: Umeå, 22 October 2021. Next week Lipums (publ) annual workshop with the Scientific Advisory Board will take place in Stockholm. The Scientific Advisory Board of Lipum constitute an invaluable resource of experience from academic research to clinical practice within the field chronic inflammatory diseases. The members contributions are expressed in specific advices along Lipums development, as well as the sharing of deep knowledge in more strategic discussions. An important forum has been the annual workshop with the Lipum team. Reflecting the progress this year’s workshop

BoMill announces a change in the Board of Directors

BoMill AB (“BoMill” or the “Company”) hereby announces that the company’s largest shareholder Capagro SAS (“Capagro”) onwards will be represented in the Board of Directors through Pierre Kiener as co-opted member and Tom Espiard-Cignaco as observer, until the next Annual General Meeting taking place in 2022, before June 30[th]. The current representative from Capagro in BoMill’s Board of Directors, Julie Peyrache, will leave Capagro for assignments outside of the group on October 22[nd], and will hence therefore also leave BoMill’s Board of Directors. The resignation of Julie Peyrache from

K-Fast Holding AB’s Nomination committee for the 2022 Annual General Meeting

The Nomination committee for the 2022 Annual General Meeting of K-Fast Holding AB (publ) has been appointed.According to the instructions for the Nomination committee adopted at K-Fast Holding AB (publ)’s Extraordinary General Meeting on 19 August 2019, the Nomination committee shall consist of four members representing the three largest shareholders in terms of number of votes as of 30 September, together with the Chairman of the Board. If a shareholder, who is entitled to appoint a representative to the Nomination committee, abstains from appointing a representative, the right to appoint

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 21st October 2021, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 26,016,081 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Crown Energy & Proger Spa have mutually agreed to terminate Proger’s advisory agreement with Crown Energy, entered in 2017

Crown Energy AB (publ) (“Crown Energy” or “Company”) announces that Crown Energy and Proger Spa. have mutually decided to end their advisory relationship and terminate the advisory service agreement, entered in 2017.Proger Spa, have been employed by Crown Energy as technical, operational, legal and safety advisor, for developing and creating the conditions for the exploitation of the rights of Crown Energy in respect of a Production Sharing Agreement contract relating to the Salah Ad Din region in Iraq. Crown Energy and Yoav Ben-Eli would like to thank Proger Spa. for their continuous

IRRAS Announces Collaboration with Aarhus University to Develop Software that Calculates Brain Compliance using its IRRAflow System

· As part of their established collaboration agreement, IRRAS, Aarhus University, and Aarhus University Hospital will collectively work to quantify brain compliance using the company’s IRRAflow system. · The combination of compliance calculations and IRRAflow treatment may provide real-time data that determines effectiveness and completion of therapeutic treatment.Stockholm, October 22, 2021 - IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the initial project from its previously announced

Interim Report January-September 2021 – Pricer AB (publ)

High delivery activity despite challenges in supply and logistics chains  Third quarter 2021 · Net sales amounted to SEK 496.0 M (565.7), a decrease of 12 percent compared to the same period last year. · Operating profit amounted to SEK 40.1 M (75.1), which corresponds to an operating margin of 8.1 percent (13.3). · Order intake was SEK 307 M (440), a decrease of 30 percent compared to the same period last year. · Order backlog amounted to SEK 396 M (754), of which the majority is expected to be delivered in Q4 2021. · Profit for the period was SEK 32.0 M (69.3). ·

Heliospectra (publ) Interim Report July - September 2021

(Gothenburg, Sweden, October 22, 2021, at 08:30 CEST)– Heliospectra AB (publ (Nasdaq First North Growth Market: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, presents its’ Interim Report for July - September 2021.Full report is enclosed to this press release and is also uploaded at https://www.heliospectra.com/investor-relations/investor-relations. SUMMARY OF REPORT: Sales And Financial Performance for the period July - September and January – September Order intake during the period July - September amounted to

235% higher operating profit during strong growth (interim report quarter three 2021)

Third Quarter (July–Sep 2021)     · Net sales amounted to TSEK 75,938 (47,411), which is an increase by 60,2% compared to the same period last year. · The gross margin amounted to 60.2% (58.1). · Operating profit before depreciation and amortization (EBITDA) amounted to TSEK 20,082 (7,979), which corresponds to an operating margin before depreciation and amortization of 26.4% (16.8). · Operating profit (EBIT) amounted to TSEK 12,736 (3,795), which corresponds to an operating margin of 16.8% (8.0). · Earnings per share before dilution amounted to SEK 0.92 (0.35) (

BioStock: Chordate Medical’s migraine study enters final stage

Since 2018, Chordate Medical has conducted a study on migraine patients to prove clinical efficacy and safety with the nerve modulating treatment method K.O.S. The patient study, conducted in Germany and Finland, is now in its final phase, and the goal is to have an article with the study results submitted to a scientific journal for publication in the spring of 2022.Read the full article at biostock.se: https://www.biostock.se/en/2021/10/chordate-medicals-migraine-study-enters-final-stage/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Arctic Paper and Rottneros are collaborating on sustainable fiber trays in Poland

Arctic Paper and Rottneros have signed a Letter of Intent regarding a 50/50 joint venture in Kostrzyn, Poland with the aim of building a molded fiber tray factory. The start-up of the new factory, which is estimated to generate an annual revenue of 9-11 MEUR, is planned for the end of 2023. The investment is expected to amount to 12-15 MEUR, corresponding to approximately 55-70 MPLN.Production will be suitable for high barrier packaging, modified atmosphere packaging with extended shelf life as well as for packaging with lesser functional demands, all based on Rottneros primary fiber. The

Invitation to telephone conference for Interim Report 1 January - 30 September 2021

Mekonomen’s Interim Report for the third quarter 2021 will be published on Friday, October 29, at 07:30 a.m CET. A telephone conference will be held at 09:00 a.m in English. Mekonomen's CEO Pehr Oscarson and CFO Åsa Källenius will present the results and respond to questions at the English speaking conference. The presentation material will be available from 8:00 a.m CET on October 29 at www.mekonomen.com under the heading Investors/IR Presentations.  Click this link to register for the

BioStock: PolarCool expands market share in France

After signing an initial 6-week evaluation agreement with French rugby team Stade Français to introduce PolarCap in France, PolarCool has signed its second evaluation agreement in France. This time the counterpart is Biarritz Olympique Pays Basque, another team from Top14, the highest league in French rugby.Read the article at biostock.se : https://www.biostock.se/en/2021/10/polarcool-expands-market-share-in-france/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se 

Alligator enters into agreements on subscription commitments with board members and senior executives

The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or "the Company") has previously, subject to approval by the Extraordinary General Meeting on 8 November 2021, resolved to carry out a rights issue of shares with preferential rights for the Company's existing shareholders of approximately SEK 257 million (the "Rights Issue"). Through the press release issued on 7 October 2021 regarding the board's decision to carry out the Rights Issue, Alligator announced that all members of the Company’s board and management with shareholdings in the Company had expressed their

Elkem to test the world's first carbon capture pilot for smelters

Elkem, a global leader in silicon-based advanced materials, today announces that it will test the world’s first carbon capture pilot for silicon smelters at its plant in Rana, Norway. The project has received financial support from Gassnova CLIMIT and is a follow-up to the company’s recently launched climate roadmap to reduce emissions towards net zero while growing supplies to the green transition.The carbon capture pilot is a collaboration between Elkem and Mo Industripark, SINTEF, Alcoa, Celsa, Ferroglobe, SMA Mineral, Norcem, Norfrakalk, Arctic Cluster Team and Aker Carbon Capture.

The Board of Directors of Calmark Sweden AB (publ) resolves to carry out a rights issue of approx. MSEK 24.9 and a directed issue of approx. MSEK 2.1, and brings forward the interim report for Q3 2021

The Board of Directors of Calmark Sweden AB (publ) (“Calmark” or the “Company”) has, on the authority of the Annual General Meeting of 18 May 2021, resolved on a rights issue of not more than 4,611,064 B shares, with preferential rights for existing shareholders in Calmark (the “Rights issue”). The Company has obtained subscription commitments corresponding to approximately 54 percent of the Rights Issue from, inter alia, Wingefors Invest AB and Creades AB (via capital insurance), as well as guarantee commitments corresponding to approximately 26 percent of the Rights Issue from Gainbridge

REPORT ON THE THIRD QUARTER 2021

STRONG SALES GROWTH AND SOLID MARGINS DESPITE SUPPLY CHAIN DISRUPTIONSTHIRD QUARTER 2021 · Net sales were SEK 5,545 m (4,466); an increase of 24%, of which 11% was organic growth. · Operating profit before depreciation and amortization (EBITDA) was SEK 987 m (867), representing a margin of 17.8% (19.4%). · Operating profit (EBIT) before items affecting comparability was SEK 785 m (690), representing a margin of 14.2% (15.5%). · Operating profit (EBIT) was SEK 762 m (676), representing a margin of 13.7% (15.1%). · Profit for the quarter was SEK 480 m (281). · Earnings per

Midsona - Interim report January - September 2021

Increased net sales with improved marginsJuly-September 2021 (third quarter) · Net sales amounted to SEK 893 million (821). · EBITDA amounted to SEK 80 million (72) before items affecting comparability, corresponding to a margin of 9.0 percent (8.8). · Profit for the period was SEK 31 million (34), corresponding to earnings per share of SEK 0.45 (0.52) before dilution and SEK 0.45 (0.51) after dilution. · Free cash flow amounted to SEK –8 million (64). · Midsona agreed to acquire Vitality and Oy, a leading Finnish player in the consumer health products category. ·

Lagercrantz Interim Report 2021/22 Q2

Second quarter (1 July – 30 September 2021) ·  Net revenue increased by 31% to MSEK 1,201 (918).  · Organically, net revenue increased by 13%. · Operating profit (EBITA) increased to MSEK 192 (132), equivalent to an operating margin of 16.0% (14.4). · Profit after financial items increased by 50% to MSEK 156 (104). · Profit after taxes increased by 43% to MSEK 116 (81). · Cash flow from operating activities increased to MSEK 113 (80). · Return on equity was 28% (22). The equity ratio at the end of the period was 34% (40). First six months (1 April – 30

Raute Corporation - Interim Report January 1-September 30, 2021

RAUTE CORPORATION INTERIM REPORT OCTOBER 22, 2021 AT 9:00 a.m. This is a summary of Raute’s Interim Report January 1-September 30, 2021. The complete report is attached to this release as a pdf file and is also available on the company’s’ website at www.raute.com.   RAUTE CORPORATION - INTERIM REPORT JANUARY 1-SEPTEMBER 30, 2021   - The Group’s net sales, EUR 98.1 million (MEUR 76.1), increased 29% on the comparison period. Order intake was very high, at EUR 154 million (MEUR 49).- Operating profit amounted to EUR -1.6 million (MEUR -2.7), up 41% on the comparison period.

Sobi publishes report for the third quarter 2021

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the third quarter 2021. Total revenue amounted to SEK 3,761 M, a 29 per cent growth at CER compared with the same period 2020. EBITA was SEK 1,166 M, resulting in an EBITA margin of 31 per cent. July – September · Total revenue SEK 3,761 M (2,970), +27 per cent, +29 per cent at constant exchange rates (CER) · Haematology revenue SEK 2,291 M (2,147), +9 per cent at CER of which Elocta® SEK 1,035 M (1,115), -6 per cent at CER, Alprolix® SEK 430 M (435), unchanged at CER, and Doptelet®

Q3 2021: Regional dynamics affecting the quarter

Significant events during the third quarter · Net sales decreased by 18% (-17% adjusted for currency changes) to SEK 159 m (195) in Q3 and decreased by 8% (-1% adjusted for currency changes) to SEK 488 m (532) for the first nine months of the year. The comparative period was positively affected by non-recurring income of around SEK 15 m. · The EBITDA margin was 27% (32%) in Q3 and 26% (28%) for the first nine months of the year. · Work started with Blis Technologies for the start of production and collaboration in the sales organization and R&D. · First tolerance study of two

myFC Holding interim report july – september 2021

Quarter july – september 2021     • Net sales amountes to 0,2 million (0,0)     • Operating profit amounted to -4,8 million (-11,0)     • Earnings per share amounted to -0,03 (-0,07) Significant events July to September    • myFC signs agreement with leading European OEM – evaluation of fuel cell solution for automated warehouse robots (AGV)    • myFC signs cooperation agreement for technical development with global bicycle system manufacturer from Japan    • Patent in India enables a large future market for myFC's technology Significant events after the period end    •

Realfiction updates on its ECHO development and Sales Activities

Realfiction Holding AB (“Realfiction” or “the Company”) announces a general update on its progress in the development of its ECHO holographic display technology and its Sales Activities.A summary of the latest progress per business area is presented below. ECHO developmentTogether with the Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP (Fraunhofer FEP), Germany, and Interuniversity Microelectronics Centre (imec), Belgium, Realfiction has been working on completing its ECHO holographic display technology integration license package. The development

There are no items matching the current filter
There are no more items matching the current filter
Back to top